Topics
High-grade gliomas | Treatment | Targeted therapy | Fexagratinib
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy | Fexagratinib
Picca A, Di Stefano AL, Savatovsky J, Ducray F, Chinot O, Moyal
EC, Augereau P, Le Rhun E, Schmitt Y, Rousseaux N, Yepnang AMM,
Estellat C, Charbonneau F, Letourneur Q, Branger DF, Meyronet D,
Fardeau C, Mokhtari K, Bielle F, Iavarone A, Sanson M.
TARGET:
A phase I/II open-label multicenter study to assess safety and
efficacy of fexagratinib in patients with relapsed/refractory FGFR
fusion-positive glioma.
Neurooncol
Adv. 2024 May 20;6(1):vdae068. doi:
10.1093/noajnl/vdae068. PMID:
38813112.
Interventional study. ˍ